// App-Quantinova.ai

P273 : Ustekinumab and guselkumab treatment results in differences in serum IL-17A, IL-17F and CRP levels in PsA patients: a comparison from ustekinumab Phase 3 and guselkumab Phase 2 programmes

Researchers

Presenter

  • Stefan Siebert

Principal Investigators

  • Matthew J Loza

  • Qingxuan Song

  • Patricia C Gorecki

  • Iain B McInnes

  • Kristen Sweet

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Janssen Research & Development, Janssen-Cilag Ltd, Spring House, PA, USA

  • Janssen Medical Affairs, Janssen-Cilag Ltd, High Wycombe, UNITED KINGDOM

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • C reactive protein

  • High sensitivity C-reactive protein

  • Interleukin 17A

Drug/Treatment

  • Ustekinumab

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved